Rockefeller Capital Management
TVTX icon

Rockefeller Capital Management’s Travere Therapeutics TVTX Stock Holding History

Rockefeller Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$241K Buy
8,109
+5,467
+207% +$163K ﹤0.01% 2386
2025
Q4 		$101K Buy
2,642
+2,487
+1,605% +$80.9K ﹤0.01% 2725
2025
Q3 		$3.71K Buy
+155
New +$2.91K ﹤0.01% 3964
2022
Q3 		– Sell
-94
Closed -$2K – 4380
2022
Q2 		$2K Sell
94
-62
-40% -$1.56K ﹤0.01% 3841
2022
Q1 		$4K Sell
156
-487
-76% -$12.9K ﹤0.01% 3450
2021
Q4 		$19K Buy
+643
New +$18.1K ﹤0.01% 2675

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rockefeller Capital Management's TVTX Position: Q1 2026 in Review

Rockefeller Capital Management increased its Travere Therapeutics (TVTX) stake by 207% in Q1 2026, buying an estimated $163K and bringing the position to 8,109 shares worth $241K. The position accounts for ﹤0.01% of the portfolio, ranked #2386.

Rockefeller Capital Management first reported a position in TVTX in Q4 2021 and has held it in 6 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Rockefeller Capital Management held 8,109 shares of Travere Therapeutics worth $241K as of Q1 2026.
  • Rockefeller Capital Management bought 5,467 Travere Therapeutics shares in Q1 2026, an estimated $163K.
  • Travere Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #2386 holding.
  • Rockefeller Capital Management first reported a position in Travere Therapeutics in Q4 2021 and has held it in 6 quarters since.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.